BackCellect Biotechnology Overview

Cellect Biotechnology Other Current Assets

Track Cellect Biotechnology's other current assets ($12M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Other Current Assets
$12.21M
40.75% YoYΔ $3.54M vs prior year quarter

Peer average / median

Loading

Cellect Biotechnology Other Current Assets History

Loading

Cellect Biotechnology vs. peers: Other Current Assets Comparison

Loading

Cellect Biotechnology Other Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Cellect Biotechnology (APOP) FAQ

Cellect Biotechnology (APOP) currently reports a other current assets of $12M as of March 2026. That compares with $8.7M in the prior-year period — up 40.8% year over year. Use the charts on this page to explore Cellect Biotechnology's other current assets history and peer comparisons.

Cellect Biotechnology's other current assets increased from $8.7M to $12M — a 40.8% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Cellect Biotechnology reported $12M in other current assets as of March 2026. That compares with $8.7M in the prior-year period — up 40.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other current assets of $12M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Cellect Biotechnology, and consider following APOP for alerts when major investors trade the stock.

Cellect Biotechnology is classified in the Healthcare sector. On other current assets, it currently shows $12M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing APOP with unrelated industries.